IRIS Accounts Production v25.1.3.33 13828575 Board of Directors Board of Directors 1.4.24 31.3.25 31.3.25 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh138285752024-03-31138285752025-03-31138285752024-04-012025-03-31138285752023-03-31138285752023-04-012024-03-31138285752024-03-3113828575ns15:EnglandWales2024-04-012025-03-3113828575ns14:PoundSterling2024-04-012025-03-3113828575ns10:Director12024-04-012025-03-3113828575ns10:Director22024-04-012025-03-3113828575ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3113828575ns10:SmallEntities2024-04-012025-03-3113828575ns10:AuditExempt-NoAccountantsReport2024-04-012025-03-3113828575ns10:SmallCompaniesRegimeForDirectorsReport2024-04-012025-03-3113828575ns10:SmallCompaniesRegimeForAccounts2024-04-012025-03-3113828575ns10:FullAccounts2024-04-012025-03-311382857512024-04-012025-03-3113828575ns10:RegisteredOffice2024-04-012025-03-3113828575ns5:CurrentFinancialInstruments2025-03-3113828575ns5:CurrentFinancialInstruments2024-03-3113828575ns5:Non-currentFinancialInstruments2025-03-3113828575ns5:Non-currentFinancialInstruments2024-03-3113828575ns5:ShareCapital2025-03-3113828575ns5:ShareCapital2024-03-3113828575ns5:RetainedEarningsAccumulatedLosses2025-03-3113828575ns5:RetainedEarningsAccumulatedLosses2024-03-3113828575ns5:NetGoodwill2024-04-012025-03-3113828575ns5:NetGoodwill2024-03-3113828575ns5:NetGoodwill2025-03-3113828575ns5:NetGoodwill2024-03-3113828575ns5:FurnitureFittings2024-03-3113828575ns5:ComputerEquipment2024-03-3113828575ns5:FurnitureFittings2024-04-012025-03-3113828575ns5:ComputerEquipment2024-04-012025-03-3113828575ns5:FurnitureFittings2025-03-3113828575ns5:ComputerEquipment2025-03-3113828575ns5:FurnitureFittings2024-03-3113828575ns5:ComputerEquipment2024-03-3113828575ns5:CostValuation2024-03-3113828575ns5:DisposalsRepaymentsInvestments2025-03-3113828575ns5:CostValuation2025-03-3113828575ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3113828575ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3113828575ns5:Non-currentFinancialInstruments2024-04-012025-03-3113828575ns5:RetainedEarningsAccumulatedLosses2024-03-3113828575ns5:RetainedEarningsAccumulatedLosses2024-04-012025-03-31
REGISTERED NUMBER: 13828575 (England and Wales)









Unaudited Financial Statements

for the Year Ended 31 March 2025

for

Lloyd Jones Pharma Limited

Lloyd Jones Pharma Limited (Registered number: 13828575)






Contents of the Financial Statements
for the Year Ended 31 March 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Lloyd Jones Pharma Limited

Company Information
for the Year Ended 31 March 2025







DIRECTORS: D J Williams
J Lloyd-Jones





REGISTERED OFFICE: 2 Radyr Farm Road
Radyr
Cardiff
CF15 8EH





REGISTERED NUMBER: 13828575 (England and Wales)





ACCOUNTANTS: P W John & Co
Parkview
23 Wadham Street
Weston-super-Mare
Somerset
BS23 1JZ

Lloyd Jones Pharma Limited (Registered number: 13828575)

Balance Sheet
31 March 2025

31.3.25 31.3.24
Notes £    £   
FIXED ASSETS
Intangible assets 4 96,740 110,560
Tangible assets 5 7,911 7,251
Investments 6 110,000 180,000
214,651 297,811

CURRENT ASSETS
Stocks 32,671 32,671
Debtors 7 229,240 180,488
Cash at bank and in hand 86,943 54,871
348,854 268,030
CREDITORS
Amounts falling due within one year 8 (196,802 ) (178,102 )
NET CURRENT ASSETS 152,052 89,928
TOTAL ASSETS LESS CURRENT
LIABILITIES

366,703

387,739

CREDITORS
Amounts falling due after more than one
year

9

(50,000

)

(180,000

)
NET ASSETS 316,703 207,739

CAPITAL AND RESERVES
Called up share capital 1,000 1,000
Retained earnings 10 315,703 206,739
316,703 207,739

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Lloyd Jones Pharma Limited (Registered number: 13828575)

Balance Sheet - continued
31 March 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 4 June 2025 and were signed on its behalf by:




D J Williams - Director



J Lloyd-Jones - Director


Lloyd Jones Pharma Limited (Registered number: 13828575)

Notes to the Financial Statements
for the Year Ended 31 March 2025

1. STATUTORY INFORMATION

Lloyd Jones Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Due to the nature of pharmacy revenue, there is an element of estimation involved. There is also some variability in the initial recognition of pharmacy revenue which is settled on the actual receipt of funds.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2022, is being amortised evenly over its estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

Fixtures and fittings - 20% on cost
Computer equipment - 20% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
The tax currently payable is based on taxable profit for the year.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 8 (2024 - 6 ) .

Lloyd Jones Pharma Limited (Registered number: 13828575)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 April 2024
and 31 March 2025 138,200
AMORTISATION
At 1 April 2024 27,640
Charge for year 13,820
At 31 March 2025 41,460
NET BOOK VALUE
At 31 March 2025 96,740
At 31 March 2024 110,560

5. TANGIBLE FIXED ASSETS
Fixtures
and Computer
fittings equipment Totals
£    £    £   
COST
At 1 April 2024 12,089 - 12,089
Additions 2,515 1,332 3,847
At 31 March 2025 14,604 1,332 15,936
DEPRECIATION
At 1 April 2024 4,838 - 4,838
Charge for year 2,921 266 3,187
At 31 March 2025 7,759 266 8,025
NET BOOK VALUE
At 31 March 2025 6,845 1,066 7,911
At 31 March 2024 7,251 - 7,251

6. FIXED ASSET INVESTMENTS
Loans to
associates
£   
At 1 April 2024 180,000
Repayment in year (70,000 )
At 31 March 2025 110,000

Relates to loans to A&R Pharma Ltd.

Lloyd Jones Pharma Limited (Registered number: 13828575)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.25 31.3.24
£    £   
Trade debtors 207,366 167,988
Other debtors 21,874 12,500
229,240 180,488

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.25 31.3.24
£    £   
Trade creditors 139,803 115,496
Taxation and social security 56,999 62,606
196,802 178,102

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.3.25 31.3.24
£    £   
Other creditors 50,000 180,000

Other creditors relates to loans from related parties.

10. RESERVES
Retained
earnings
£   

At 1 April 2024 206,739
Profit for the year 149,178
Dividends (40,214 )
At 31 March 2025 315,703